WEBULL
News
CDNA
19.19
-1.54%
-0.30
CareDx Wins Preliminary Court Approval for Derivative Settlement
TipRanks · 6h ago
CAREDX INC: SHALL ENGAGE OUTSIDE COUNSEL BY NO LATER THAN END OF Q1 OF 2026
Reuters · 7h ago
CareDx Provides Notice of Proposed Derivative Settlement
Barchart · 13h ago
CareDx Adopts Majority Vote Standard for Director Elections
Reuters · 3d ago
CareDx Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 3d ago
Wells Fargo Maintains Equal-Weight on CareDx, Raises Price Target to $18
Benzinga · 3d ago
CareDx price target raised to $18 from $14 at Wells Fargo
TipRanks · 3d ago
Weekly Report: what happened at CDNA last week (1208-1212)?
Weekly Report · 3d ago
U.S. RESEARCH ROUNDUP-Applied Materials, Coca-Cola, Glacier Bancorp
Reuters · 3d ago
Weekly Report: what happened at CDNA last week (1201-1205)?
Weekly Report · 12/08 09:20
CareDx Inc. Secretary and General Counsel Jeffrey Adam Novack Reports Sale of Common Shares
Reuters · 12/05 21:08
Weekly Report: what happened at CDNA last week (1124-1128)?
Weekly Report · 12/01 09:19
Craig-Hallum Keeps Their Buy Rating on CareDx (CDNA)
TipRanks · 11/25 14:25
CareDx Publishes Data On Third Manuscript From Surveillance HeartCare Outcomes Registry Shows Participants With Positive HeartCare Results Found At Higher Risk For Rejection-Related Complications
Benzinga · 11/24 21:10
CareDx SHORE Study Shows HeartCare Test Triples Risk Prediction for Heart Transplant Patients
Reuters · 11/24 21:06
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
Barchart · 11/24 15:05
Weekly Report: what happened at CDNA last week (1117-1121)?
Weekly Report · 11/24 09:20
Weekly Report: what happened at CDNA last week (1110-1114)?
Weekly Report · 11/17 09:20
CareDx Inc. Secretary and General Counsel Jeffrey Adam Novack Reports Disposal of Common Shares
Reuters · 11/10 21:15
CareDx Inc. to Present at Stephens Investment Conference
Reuters · 11/10 13:05
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.